• KOLs Community
    • Idarucizumab
    • Idarucizumab Dabigatran
    • Yukako Ogi
    • Yukako Ogi

      Yukako Ogi

      Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan



      KOL Resume for Yukako Ogi


      Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan


      Prominent publications by Yukako Ogi

      KOL-Index: 5007

      INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serious bleeding (Group A) or required an urgent procedure (Group B).

      METHODS: The primary endpoint was the incidence of adverse drug reactions (ADRs). The secondary endpoint was the maximum extent ...

      Known for Japanese Patients | Idarucizumab Dabigatran

      Key People For Idarucizumab Dabigatran

      Top KOLs in the world
      Paul A Reilly
      atrial fibrillation dabigatran warfarin major bleeding
      Joachim Stangier
      dabigatran etexilate hepatic impairment total hip replacement
      Stephan Glund
      skeletal muscle dabigatran reversal glucose transport
      John W A Eikelboom
      atrial fibrillation ischemic stroke major bleeding
      Jeffrey Ian Weitz
      venous thromboembolism major bleeding pulmonary embolism
      Joanne van Ryn
      dabigatran etexilate specific antidote blood loss

      Yukako Ogi:Expert Impact

      Concepts for whichYukako Ogihas direct influence:Idarucizumab dabigatran.

      Yukako Ogi:KOL impact

      Concepts related to the work of other authors for whichfor which Yukako Ogi has influence:Reversal agents,  Severe bleeding,  Management atrial fibrillation,  Effective hemostasis 95,  Patient characteristics dabigatran,  Availability idarucizumab,  Study 110 bid.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.